IMPLANET Announces Its 2022 Financial Calendar

Rhea-AI Summary

IMPLANET, listed on Euronext Paris under the symbol ALIMP, has announced its financial information publication schedule for 2022. The schedule includes important dates such as the 2021 Full-Year Results on March 15, 2022, and subsequent quarterly revenue reports throughout the year. IMPLANET specializes in vertebral implants and employs 29 staff, achieving a consolidated revenue of €6.1 million in 2021. The company has a notable product, JAZZ®, which has received regulatory approvals including the FDA clearance in the U.S.

Positive

• Achieved a consolidated revenue of €6.1 million in 2021.
• JAZZ® product received FDA clearance in the U.S., CE mark in Europe, and ANVISA approval in Brazil.

Negative

• None.

BORDEAUX, France & BOSTON--(BUSINESS WIRE)-- Regulatory News:

IMPLANET (Paris:ALIMP) (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specialized in vertebral implants, today announces its schedule for the publication of financial information for 2022Etats-Unis de son expansion commerciale aux Etats-Unis,.

Event	Dates*
2021 Full-Year Results	March 15, 2022
2022 First-Quarter Revenue	April 19, 2022
Annual General Meeting	April 26, 2022
2022 First-Half Revenue	July 11, 2022
2022 First-Half Results	September 20, 2022
2022 Third-Quarter Revenue	October 18, 2022

(*): These dates can be subject to modifications. Press releases will be published after market close.

Upcoming financial event:
– 2021 Full-Year Results, on March 15, 2022 after market close.

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity revolves around a comprehensive innovative solution for improving the treatment of spinal pathologies (JAZZ®) complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s tried-and-tested orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark in Europe and ANVISA approval in Brazil. IMPLANET employs 29 staff and recorded a consolidated revenue of €6.1 million in 2021. Based near Bordeaux in France, IMPLANET opened a US subsidiary in Boston in 2013. IMPLANET is listed on the Euronext Growth market in Paris. For further information, please visit www.implanet.com.

The Company would like to remind readers that the table for monitoring the equity line (OCA, BSA) and the number of shares outstanding is available on its website: http://www.implanet-invest.com/suivi-des-actions-80

View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005550/en/

IMPLANET

Ludovic Lastennet, CEO

David Dieumegard, CFO

Tel.: +33 (0)5 57 99 55 55

investors@Implanet.com

NewCap

Investor Relations

Mathilde Bohin

Nicolas Fossiez

Tel.: +33 (0)1 44 71 94 94

implanet@newcap.eu

NewCap

Media Relations

Nicolas Merigeau

Tel.: +33 (0)1 44 71 94 94

implanet@newcap.eu

Source: IMPLANET

FAQ

What is the financial information publication schedule for IMPLANET in 2022?

IMPLANET's publication schedule includes key dates such as the 2021 Full-Year Results on March 15, 2022, and quarterly revenue reports throughout the year.

When will IMPLANET announce its 2021 Full-Year Results?

IMPLANET will announce its 2021 Full-Year Results on March 15, 2022, after market close.

What are the upcoming financial events for IMPLANET in 2022?

Upcoming events include the 2022 First-Quarter Revenue on April 19, 2022, and the Annual General Meeting on April 26, 2022.

What is the revenue of IMPLANET for the year 2021?

IMPLANET recorded a consolidated revenue of €6.1 million in 2021.

What is the significance of the JAZZ® product for IMPLANET?

The JAZZ® product is key for IMPLANET as it has received multiple regulatory approvals, indicating its market readiness and potential for sales growth.